Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma